Krsnaa Diagnost. Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹240 Cr +31.1% YoYSee revenue, profit and what management said. You are viewing Q4 FY25.
KD

Krsnaa Diagnost.

Q4 FY25

Krsnaa Diagnostics Q4 FY25 earnings call: Revenue & Margins

Q4 FY25 earnings call: what management said on revenue, margins and capex.

Revenue
₹175Cr
+10.1% YoY
+6.1% QoQ
Net profit
₹21Cr
+16.7% YoY
−4.5% QoQ
Margin
31%
+4 pp YoY
+2 pp QoQ
Price₹562
Market cap₹1.9K Cr
P/E19.2

The short version

Growth momentum expected to resume in FY '26 with aspirations to surpass previous levels. FY25 revenue grew 16% YoY to INR 7,172 million; EBITDA rose 34% to INR 1,958 million with a 27% margin; net profit up 37% to INR 776 million with 11% margin.

From Krsnaa Diagnost.'s Q4 FY25 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Growth momentum expected to resume in FY '26 with aspirations to surpass previous levels.
  • Radiology and pathology volumes are increasing, with a balanced 50:50 revenue mix.
  • Younger centers, especially in radiology, projected to mature and contribute significantly from FY '26 onwards.
  • Retail business (B2C) anticipated to contribute 5-8% of revenue in FY '26, growing from ~3.5% in Q4 FY '25.
  • Retail touch points are expanding rapidly (nearly 4x growth in 1 year), supporting growth.
  • Overall revenue growth target is around 16%+ for FY '26, with expectations to outperform the industry.

2 more points from Krsnaa Diagnost.'s call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Krsnaa Diagnost. said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • For FY '26, planned investments are in the range of INR 100 to 150 crores.
  • Due to adoption of an asset-light model, actual cash outflow is expected to be significantly less than INR 100 crores.
  • Investments will focus on implementing sizable tenders won at favorable rates.
  • Capex mainly targets new radiology centers in Madhya Pradesh, Maharashtra, Delhi, and pathology collection centers in Assam and Orissa.
  • Collection centers require minimal capex, primarily for basic infrastructure like refrigerators and basic test equipment.
  • Strategic partnerships involve deferred equipment payments with 7% annual interest to support infrastructure.

2 more points from Krsnaa Diagnost.'s call on capex

Create a free account to keep reading this call

Fundraising & Capital Structure

See what Krsnaa Diagnost. said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • The company continues to win tenders and deepen its presence in Tier 2 and Tier 3 cities.
  • There is a strong forward visibility supported by the order book and upcoming project pipeline.
  • Various sizable tenders already won are expected to require investments of about INR 100-150 crores in FY '26.

2 more points from Krsnaa Diagnost.'s call on order book

Create a free account to keep reading this call

Krsnaa Diagnost. — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Krsnaa Diagnost. Q4 FY25 results — key figures

Krsnaa Diagnost. Q4 FY25 reported results vs Q4 FY24, ₹ crore
₹ CrQ4 FY25Q4 FY24YoYQ3 FY25QoQ
Revenue175159+10.1%165+6.1%
Operating profit (EBITDA)5343+23.3%48+10.4%
Operating margin31%27%+4 pp29%+2 pp
Profit before tax2922+31.8%28+3.6%
Net profit (PAT)2118+16.7%22-4.5%
EPS (₹)6.535.70+14.6%6.69-2.4%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹240 Cr, net profit ₹25 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Healthcare Services this season

  • 3B Blackbio (Q4 FY25)

    UK subsidiary (TRUPCR Europe Limited) revenue FY 2024-25: GBP 1,287,580, a 94% increase over FY 2023-24 GBP 664,059. Key concall takeaways from 3B Blackbio DX…

  • Apollo Hospitals (Q4 FY25)

    . Key concall takeaways from Apollo Hospitals Enterprise Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.

  • Shalby (Q4 FY25)

    Implant business is in high-growth mode: 4x growth in Indonesia, 35-40% growth in U.S., and 2.5x growth in India reported last year. Key concall takeaways from…

  • Narayana Hrudaya (Q4 FY25)

    Capex is split between regular maintenance/replacement (~INR 300 crores) and new greenfield/brownfield capacity (~INR 450 crores) with some variability based…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Krsnaa Diagnost. and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Krsnaa Diagnost. Q4 FY25 results?

Growth momentum expected to resume in FY '26 with aspirations to surpass previous levels. FY25 revenue grew 16% YoY to INR 7,172 million; EBITDA rose 34% to INR 1,958 million with a 27% margin; net profit up 37% to INR 776 million with 11% margin.

What is Krsnaa Diagnost. share price analysis?

Krsnaa Diagnost. currently shows a neutral. The stock trades at a P/E of 19.1 with a market cap of ₹1,866 Cr. Investors should review the full earnings analysis for detailed insights.

Is Krsnaa Diagnost. planning capital expenditure?

For FY '26, planned investments are in the range of INR 100 to 150 crores.

Keep Krsnaa Diagnost. on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.